Clopidogrel and Thrombotic Thrombocytopenic Purpura
To the Editor: Clopidogrel is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and death from vascular causes) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease. This indication...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2000-10, Vol.343 (16), p.1191-1194 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1194 |
|---|---|
| container_issue | 16 |
| container_start_page | 1191 |
| container_title | The New England journal of medicine |
| container_volume | 343 |
| creator | Trontell, A E Honig, P K |
| description | To the Editor:
Clopidogrel is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and death from vascular causes) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease. This indication is based on the results of a clinical trial, involving 19,185 patients, in which clopidogrel was compared with aspirin in patients at risk for ischemic events. The study's steering committee estimated that clopidogrel would prevent about 24 major clinical events for every 1000 patients treated for one year.
1
Clopidogrel was approved by the Food and Drug Administration (FDA) in November 1997 and . . . |
| doi_str_mv | 10.1056/NEJM200010193431612 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_223952840</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>62939990</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-ea05cb1f78b47f97d2e79e84c60c5410ad23175f1f39af45ca5dc9925b228c173</originalsourceid><addsrcrecordid>eNqFkEtPwzAQhC0EoqXwC5BQxRUFdv2I4yOqWh4qj0M5W47jQKsmDnZy6L8nVYu4IDjtavXN7GgIOUe4RhDpzfP08YkCAAIqxhmmSA_IEAVjCeeQHpIhAM0SLhUbkJMYV7CFuTomA0TgKAUdEjZZ-2ZZ-Pfg1mNTF-PFR_BV7tul_V7tpvWNq_vDaxeaLphTclSadXRn-zkib7PpYnKfzF_uHia388QKqtrEGRA2x1JmOZelkgV1UrmM2xSs4AimoKwPUWLJlCm5sEYUVikqckozi5KNyOXOtwn-s3Ox1Svfhbp_qSllStCMw38Qz5TYQmwH2eBjDK7UTVhWJmw0gt6WqX8ps1dd7K27vHLFj2bfXg9c7YCqirp2q-pPuy-hZXlW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223948950</pqid></control><display><type>article</type><title>Clopidogrel and Thrombotic Thrombocytopenic Purpura</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Trontell, A E ; Honig, P K</creator><creatorcontrib>Trontell, A E ; Honig, P K</creatorcontrib><description>To the Editor:
Clopidogrel is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and death from vascular causes) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease. This indication is based on the results of a clinical trial, involving 19,185 patients, in which clopidogrel was compared with aspirin in patients at risk for ischemic events. The study's steering committee estimated that clopidogrel would prevent about 24 major clinical events for every 1000 patients treated for one year.
1
Clopidogrel was approved by the Food and Drug Administration (FDA) in November 1997 and . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM200010193431612</identifier><identifier>PMID: 11041752</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Drug Labeling ; Humans ; Platelet Aggregation Inhibitors - adverse effects ; Product Surveillance, Postmarketing ; Purpura, Thrombotic Thrombocytopenic - chemically induced ; Ticlopidine - adverse effects ; Ticlopidine - analogs & derivatives ; Ticlopidine - therapeutic use ; United States ; United States Food and Drug Administration</subject><ispartof>The New England journal of medicine, 2000-10, Vol.343 (16), p.1191-1194</ispartof><rights>Copyright © 2000 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright National Library of Medicine - MEDLINE Abstracts Oct 19 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-ea05cb1f78b47f97d2e79e84c60c5410ad23175f1f39af45ca5dc9925b228c173</citedby><cites>FETCH-LOGICAL-c529t-ea05cb1f78b47f97d2e79e84c60c5410ad23175f1f39af45ca5dc9925b228c173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM200010193431612$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM200010193431612$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11041752$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Trontell, A E</creatorcontrib><creatorcontrib>Honig, P K</creatorcontrib><title>Clopidogrel and Thrombotic Thrombocytopenic Purpura</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Clopidogrel is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and death from vascular causes) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease. This indication is based on the results of a clinical trial, involving 19,185 patients, in which clopidogrel was compared with aspirin in patients at risk for ischemic events. The study's steering committee estimated that clopidogrel would prevent about 24 major clinical events for every 1000 patients treated for one year.
1
Clopidogrel was approved by the Food and Drug Administration (FDA) in November 1997 and . . .</description><subject>Drug Labeling</subject><subject>Humans</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Product Surveillance, Postmarketing</subject><subject>Purpura, Thrombotic Thrombocytopenic - chemically induced</subject><subject>Ticlopidine - adverse effects</subject><subject>Ticlopidine - analogs & derivatives</subject><subject>Ticlopidine - therapeutic use</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkEtPwzAQhC0EoqXwC5BQxRUFdv2I4yOqWh4qj0M5W47jQKsmDnZy6L8nVYu4IDjtavXN7GgIOUe4RhDpzfP08YkCAAIqxhmmSA_IEAVjCeeQHpIhAM0SLhUbkJMYV7CFuTomA0TgKAUdEjZZ-2ZZ-Pfg1mNTF-PFR_BV7tul_V7tpvWNq_vDaxeaLphTclSadXRn-zkib7PpYnKfzF_uHia388QKqtrEGRA2x1JmOZelkgV1UrmM2xSs4AimoKwPUWLJlCm5sEYUVikqckozi5KNyOXOtwn-s3Ox1Svfhbp_qSllStCMw38Qz5TYQmwH2eBjDK7UTVhWJmw0gt6WqX8ps1dd7K27vHLFj2bfXg9c7YCqirp2q-pPuy-hZXlW</recordid><startdate>20001019</startdate><enddate>20001019</enddate><creator>Trontell, A E</creator><creator>Honig, P K</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20001019</creationdate><title>Clopidogrel and Thrombotic Thrombocytopenic Purpura</title><author>Trontell, A E ; Honig, P K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-ea05cb1f78b47f97d2e79e84c60c5410ad23175f1f39af45ca5dc9925b228c173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Drug Labeling</topic><topic>Humans</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Product Surveillance, Postmarketing</topic><topic>Purpura, Thrombotic Thrombocytopenic - chemically induced</topic><topic>Ticlopidine - adverse effects</topic><topic>Ticlopidine - analogs & derivatives</topic><topic>Ticlopidine - therapeutic use</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Trontell, A E</creatorcontrib><creatorcontrib>Honig, P K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trontell, A E</au><au>Honig, P K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clopidogrel and Thrombotic Thrombocytopenic Purpura</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2000-10-19</date><risdate>2000</risdate><volume>343</volume><issue>16</issue><spage>1191</spage><epage>1194</epage><pages>1191-1194</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>To the Editor:
Clopidogrel is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and death from vascular causes) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease. This indication is based on the results of a clinical trial, involving 19,185 patients, in which clopidogrel was compared with aspirin in patients at risk for ischemic events. The study's steering committee estimated that clopidogrel would prevent about 24 major clinical events for every 1000 patients treated for one year.
1
Clopidogrel was approved by the Food and Drug Administration (FDA) in November 1997 and . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>11041752</pmid><doi>10.1056/NEJM200010193431612</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2000-10, Vol.343 (16), p.1191-1194 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_223952840 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Drug Labeling Humans Platelet Aggregation Inhibitors - adverse effects Product Surveillance, Postmarketing Purpura, Thrombotic Thrombocytopenic - chemically induced Ticlopidine - adverse effects Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use United States United States Food and Drug Administration |
| title | Clopidogrel and Thrombotic Thrombocytopenic Purpura |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T10%3A02%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clopidogrel%20and%20Thrombotic%20Thrombocytopenic%20Purpura&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Trontell,%20A%20E&rft.date=2000-10-19&rft.volume=343&rft.issue=16&rft.spage=1191&rft.epage=1194&rft.pages=1191-1194&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM200010193431612&rft_dat=%3Cproquest_cross%3E62939990%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223948950&rft_id=info:pmid/11041752&rfr_iscdi=true |